共 489 条
[41]
Tigas S(2021)Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study Diabetes Obes Metab 11 567-1534
[42]
Bargiota A(2019)Improved time in range and glycemic variability with sotagliflozin in combination with insulin in adults with type 1 diabetes: a pooled analysis of 24-week continuous glucose monitoring data from the IntanDEM program Diabetes Care 94 26-649
[43]
Sampanis C(2020)Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes Diabetes ther: res treat educ diabetes relat disord 9 1831-514
[44]
Cherubini V(2019)Urinary glucose excretion after dapagliflozin treatment: an exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus Diabetes Obes Metab 96 e7201-1483
[45]
Gesuita R(2020)Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption J Clin Endocrinol Metab 2 691-92
[46]
Strele I(2015)Severe hypoglycemia and coronary artery calcification during the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study Diabetes Res Clin Pract 10 1531-27
[47]
Pildava S(2012)The physiology and pathophysiology of the neural control of the counterregulatory response Am J Physiol Regul Integr Comp Physiol 58 640-undefined
[48]
Coppell KJ(1988)Weight gain associated with intensive therapy in the diabetes control and complications trial Diabetes Care 7 2824-undefined
[49]
Magee G(2018)Renoprotective effects of sodium-glucose cotransporter-2 inhibitors Kidney Int 55 503-undefined
[50]
Cooper JG(2018)Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward? Diabetes ther: res treat educ diabetes relat disord 37 1480-undefined